Alessandro M Vannucchi Selected Research

Thrombocytosis (Thrombocythemia)

7/2022	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
1/2020	Polycythemia vera: the current status of preclinical models and therapeutic targets.
11/2018	Prefibrotic myelofibrosis: treatment algorithm 2018.
1/2016	Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.
12/2011	Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
8/2011	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
8/2007	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro M Vannucchi Research Topics

Disease

84	Primary Myelofibrosis (Myelosclerosis) 07/2022 - 06/2004
56	Neoplasms (Cancer) 05/2022 - 05/2002
52	Polycythemia Vera 12/2022 - 09/2005
39	Essential Thrombocythemia 12/2022 - 09/2005
25	Splenomegaly 07/2022 - 12/2007
21	Thrombosis (Thrombus) 12/2021 - 08/2007
16	Anemia 12/2021 - 01/2011
15	Thrombocytopenia (Thrombopenia) 07/2022 - 03/2012
9	Leukemia 01/2020 - 05/2002
8	Pruritus (Itching) 12/2021 - 12/2007
7	Thrombocytosis (Thrombocythemia) 07/2022 - 08/2007
7	Hemorrhage 01/2022 - 01/2008
6	Venous Thrombosis (Deep-Vein Thrombosis) 12/2021 - 07/2012
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 10/2009
5	Fibrosis (Cirrhosis) 04/2014 - 05/2009
4	Disease Progression 01/2020 - 07/2011
4	Leukocytosis (Pleocytosis) 01/2020 - 05/2012
4	Myeloproliferative Disorders (Myeloproliferative Disorder) 10/2019 - 09/2008
4	Fatigue 01/2017 - 07/2011
3	Multiple Myeloma 11/2021 - 03/2005
3	Polycythemia (Erythrocytosis) 01/2020 - 08/2007
3	Infections 01/2020 - 01/2015
3	Hematologic Neoplasms (Hematological Malignancy) 11/2018 - 01/2015
3	Pain (Aches) 01/2017 - 07/2013
2	Systemic Mastocytosis 11/2022 - 12/2021
2	Portal Hypertension 01/2022 - 02/2011
2	Inflammation (Inflammations) 12/2018 - 02/2011
2	Sepsis (Septicemia) 02/2018 - 05/2017
2	Fever (Fevers) 05/2017 - 07/2013
2	Cytopenia 05/2017 - 06/2016
2	Heart Failure 05/2017 - 07/2010
2	Hyperplasia 04/2014 - 05/2009
2	Hypereosinophilic Syndrome (Loeffler Endocarditis) 07/2010 - 12/2009
1	Hypertension (High Blood Pressure) 07/2022
1	Cerebral Hemorrhage 12/2021
1	Eosinophilia 06/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2021
1	Blast Crisis (Blast Phase) 01/2021

Drug/Important Bio-Agent (IBA)

47	ruxolitinibIBA 07/2022 - 03/2012
22	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2022 - 08/2010
13	Janus Kinase InhibitorsIBA 07/2022 - 12/2013
12	Janus KinasesIBA 07/2022 - 11/2010
12	Hemoglobins (Hemoglobin)IBA 12/2021 - 05/2002
10	Pharmaceutical PreparationsIBA 12/2021 - 05/2002
10	CalreticulinIBA 01/2019 - 03/2014
9	Janus Kinase 2IBA 05/2021 - 08/2007
8	fedratinibIBA 01/2022 - 08/2015
8	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 01/2007
7	CytokinesIBA 01/2020 - 12/2004
7	Syntex adjuvant formulationIBA 12/2017 - 07/2011
6	MicroRNAs (MicroRNA)IBA 01/2019 - 11/2007
5	InterferonsIBA 12/2022 - 01/2017
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2009
4	Janus Kinase 1IBA 10/2021 - 12/2012
4	givinostatIBA 01/2021 - 08/2010
4	Thrombopoietin (c-mpl Ligand)IBA 01/2020 - 06/2004
4	Everolimus FDA Link 11/2017 - 08/2011
4	Immunologic Factors (Immunomodulators)IBA 01/2017 - 02/2011
4	Reticulin (Reticular Fiber)IBA 04/2014 - 05/2009
3	imetelstatIBA 07/2022 - 10/2021
3	Biomarkers (Surrogate Marker)IBA 10/2021 - 02/2011
3	Phosphotransferases (Kinase)IBA 10/2021 - 12/2013
3	AnticoagulantsIBA 10/2021 - 03/2008
3	pomalidomideIBA 01/2021 - 01/2011
3	Histone Deacetylase InhibitorsIBA 01/2020 - 08/2010
3	Biological ProductsIBA 10/2018 - 12/2010
3	anagrelide (Agrylin)FDA LinkGeneric 01/2017 - 12/2011
3	Erythropoietin FDA Link 04/2014 - 06/2011
3	Imatinib Mesylate (Gleevec)FDA Link 11/2010 - 12/2009
2	avapritinibIBA 11/2022 - 12/2021
2	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2022 - 10/2021
2	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2022 - 05/2017
2	Interleukin-3 (Interleukin 3)IBA 01/2020 - 11/2009
2	Thrombopoietin ReceptorsIBA 01/2020 - 12/2010
2	Dihydrotachysterol (AT 10)IBA 01/2019 - 08/2011
2	RNA (Ribonucleic Acid)IBA 01/2015 - 03/2012
2	Messenger RNA (mRNA)IBA 09/2014 - 11/2009
2	TOR Serine-Threonine KinasesIBA 01/2013 - 07/2011
2	bepafantIBA 10/2009 - 05/2002
1	Interleukin-1 Receptor-Associated KinasesIBA 01/2022
1	RG7388IBA 01/2022
1	Busulfan (Busulfex)FDA Link 12/2021
1	VaccinesIBA 12/2021
1	daratumumabIBA 11/2021
1	Cytokine Receptors (Cytokine Receptor)IBA 06/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2021
1	Lenalidomide (CC 5013)FDA Link 01/2021
1	ChromatinIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Azacitidine (5 Azacytidine)FDA Link 01/2021
1	Decitabine FDA Link 01/2021
1	Interleukin-13IBA 01/2021

Therapy/Procedure

54	Therapeutics 12/2022 - 05/2002
5	Splenectomy 01/2021 - 12/2007
3	Drug Therapy (Chemotherapy) 10/2018 - 08/2007
3	Erythrocyte Transfusion 02/2018 - 01/2017
2	Hematopoietic Stem Cell Transplantation 01/2020 - 08/2014
2	Drug Tapering 02/2018 - 03/2012
2	Stem Cell Transplantation 01/2018 - 03/2009
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 01/2022